{"id":1625,"date":"2014-10-01T12:04:00","date_gmt":"2014-10-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/erratum-2"},"modified":"2014-10-01T12:04:00","modified_gmt":"2014-10-01T10:04:00","slug":"erratum-2","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/erratum-2","title":{"rendered":"Erratum"},"content":{"rendered":"<p>In unserem Hauptartikel September &#8222;Kombinationsbehandlung der COPD mit langwirkenden Bronchodilatatoren&#8220; (AMB 2014, 48, 65) ist uns ein Fehler unterlaufen. Es muss in Tab. 1 unter Zeile Schweregrad C und der Spalte Empfohlene Erstlinientherapie korrekt hei\u00dfen: &#8222;ICS plus LABA oder LAMA&#8220; (gemeint ist LAMA mono). Wir haben dies in unserer Internetausgabe korrigiert.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In unserem Hauptartikel September &#8222;Kombinationsbehandlung der COPD mit langwirkenden Bronchodilatatoren&#8220; (AMB 2014, 48, 65) ist uns ein Fehler unterlaufen. Es muss in Tab. 1 unter Zeile Schweregrad C und der Spalte Empfohlene Erstlinientherapie korrekt hei\u00dfen: &#8222;ICS plus LABA oder LAMA&#8220; (gemeint ist LAMA mono). Wir haben dies in unserer Internetausgabe korrigiert.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[468,466,471,1020,1018,2835,779,2838,2837,2834,2836],"class_list":["post-1625","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-chronisch-obstruktive-lungenerkrankung","tag-chronische-bronchitis","tag-copd","tag-g-ba","tag-gemeinsamer-bundesausschuss","tag-glycopyrronium","tag-gold","tag-indacaterol","tag-indacaterol-glycopyrronium","tag-laba","tag-lama"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1625"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1625\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}